[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586750":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":40,"responsibleParty":56,"collaborators":26,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":26,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Shanghai Mental Health Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"the active-tACS group","EXPERIMENTAL","This trial consists of a 2-week intensified intervention phase (40 sessions), followed by a 4-week observation period. On the first day of the intervention, participants will receive a tACS session, followed by triple-daily tACS sessions administered for 13 consecutive days.",[13],"Device: Active-tACS",{"label":15,"type":16,"description":17,"interventionNames":18},"the sham-tACS group","SHAM_COMPARATOR","Participants in the sham-tACS group will undergo the same protocol, utilizing a sham tACS incapable of delivering active stimulation. They will be kept unaware of their assigned treatment.",[19],"Device: Sham-tACS",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Active-tACS","Participants were comfortably positioned on a lounge chair and received alternating current stimulation using an FDA-approved tACS device (Nexalin Technology, Inc., Houston, TX, USA). Electrodes were evenly placed across the forehead and mastoid regions. Trained nurses administered the tACS according to standardized protocols.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Sham-tACS","The sham tACS device will resemble the active stimulation device in appearance, weight, size, color, and odor, ensuring indistinguishability for the patients. Throughout the entire intervention period, each participant will be allocated to the same tACS device, regardless of whether it delivers active or sham stimulation.",[15],[32],{"name":33,"affiliation":5,"role":34},"TianHong Zhang, Doctor","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","13127577024","zhang_tianhong@126.com",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Shanghai","Shanghai Municipality","200030","China","CN",{"type":49,"coordinates":50},"Point",[51,52],121.45806,31.22222,{"lat":52,"lon":51},[55],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},{"type":34,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Tianhong ZHANG","Associate Professor","100586750","efficacy-of-triple-daily-15ma-tacs-on-adolescent-nssi-100586750",false,"NCT06919432","Efficacy of Triple-daily 15mA tACS on Adolescent NSSI","Efficacy of Triple-daily 15mA Transcranial Alternating Current Stimulation on Adolescent Non-suicidal Self-injury (NSSI): a Double-blind, Randomized, Sham-controlled Trial","Inclusion Criteria:\n\n* Diagnosis of NSSI based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria section 3 diagnostic criteria.\n* Five or more NSSI episodes in the past year and at least one NSSI episode in the past month.\n* Age between 12 and 21 years.\n* Informed consent from parents or legal guardians.\n* Informed consent from participants aged 15 years and above.\n\nExclusion Criteria:\n\n* Current or history of organic brain disorders or neurological disorders.\n* Elevated or imminent suicidal risk, as assessed by clinicians during routine screening.\n* Previous or current exposure to electroconvulsive therapy (ECT), modified ECT, TMS, transcranial direct current stimulation (tDCS), tACS, or other neurostimulation treatments.\n* Presence of cochlear implants, cardiac pacemakers, implanted devices, or metal in the brain.\n* Previous or current use of psychotropic medication.\n* Pregnancy or lactation.\n* Participation in another concurrent clinical trial.\n* Refusal to provide informed consent to participate in the trial.\n* Other circumstances deemed unsuitable for participation by researchers.","ALL","12 Years","21 Years",{"count":70,"type":71},66,"ESTIMATED","INTERVENTIONAL",[74],"NA","In order to assess the clinical efficacy of triple-daily 15mA-tACS stimulation by comparing the effects of active and sham tACS interventions on driving improvements in adolescent Nonsuicidal Self-Injury(NSSI), participants will be randomly assigned to either the active or sham tACS group. This trial consists of a 2-week intensified intervention phase (40 sessions), followed by a 4-week observation period. The key hypothesis is that triple-daily 15mA-tACS stimulation will enhance clinical recovery compared to sham stimulation.",[77],"Self-Injurious Behavior",[79,80],"Transcranial Alternating Current Stimulation (tACS)","non-invasive brain stimulation","2025-06-11",{"date":83,"type":84},"2025-06-12","ACTUAL",{"date":86,"type":84},"2025-05-01",{"date":88,"type":71},"2027-09-30",{"name":5,"class":6},1]